Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 9/20 | 0.64 |
| ▸ | PREP | P48147 | 2/20 | 0.52 |
| ▸ | F13A1 | P00488 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | TGM1 | P22735 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14711221 | 1.00 | CCR1 (0.64) | CCR1PREPF13A1TGM2TGM1 | |
| SCHEMBL14710994 | 0.89 | CCR1 (0.59) | CCR1F13A1TGM2TGM1CTSK | |
| SCHEMBL14711222 | 0.89 | CCR1 (0.59) | CCR1F13A1TGM2TGM1CTSK | |
| SCHEMBL14711037 | 0.89 | CCR1 (0.59) | CCR1F13A1TGM2TGM1CTSK | |
| SCHEMBL6747802 | 0.84 | HTT (0.61) | CCR1 | |
| SCHEMBL14710936 | 0.82 | CCR1 (0.51) | CCR1PREPF13A1TGM2TGM1 | |
| SCHEMBL8206098 | 0.81 | PREP (0.61) | CCR1PREPCTSKCTSLCTSB | |
| SCHEMBL11254461 | 0.81 | PREP (0.61) | CCR1PREPCTSKCTSLCTSB | |
| SCHEMBL8206101 | 0.81 | PREP (0.61) | CCR1PREPCTSKCTSLCTSB | |
| SCHEMBL11261467 | 0.81 | PREP (0.61) | CCR1PREPCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | CCR1 1107/4885PREP 1139/4885F13A1 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.